CuraTeQ Biologics announces Phase1 clinical study outcome of BP11 product March 18, 2024 CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Ltd, announced that their Omalizumab biosimilar candidate BP11 has met the Phase 1 trial end points vis-à-vis the EU and US sourced reference... Trending Western lifestyle main cause for surge in Pancreatic Cancer in India: Experts Amid alarming air pollution, Doctors question NMC’s removal of Respiratory Medicine dept No, not only risks, spicy foods have benefits too, know here Latest Western lifestyle main cause for surge in Pancreatic Cancer in India: Experts Amid alarming air pollution, Doctors question NMC’s removal of Respiratory Medicine dept Air pollution spikes inflammation in patients with heart disease: Study Health ministry writes to all states on alarming air pollution, fire incidents
